文献速递其他结缔组织病血管炎

基质裂解素2(MMP10)作为系统性硬化相关肺动脉高压血管重塑的新型介质

Role of Stromelysin 2 (Matrix Metalloproteinase 10) as a Novel Mediator of Vascular Remodeling Underlying Pulmonary Hypertension Associated With Systemic Sclerosis.
PubMed 文献 · Arthritis Rheumatol · 2017-10-17

本研究通过微阵列分析发现MMP10在系统性硬化相关肺动脉高压(SSc-PH)患者内皮祖细胞来源内皮细胞中上调,血清proMMP10升高且肺血管壁MMP10染色增强;在Fra-2-Tg小鼠中中和MMP10抗体可逆转已建立的PH并减轻肺血管重塑,提示MMP10是潜在治疗靶点。

要点

  • MMP10是SSc-PH中内皮祖细胞来源内皮细胞上调最显著的基因。
  • SSc-PH患者血清proMMP10水平及肺血管壁MMP10表达均升高。
  • 抗MMP10抗体可逆转Fra-2-Tg小鼠已建立的PH并减轻肺血管重塑。

核心结论

  • MMP10是SSc相关肺动脉高压的新型候选基因,其阻断可减轻小鼠模型中的肺动脉高压和肺血管重塑。

研究设计与样本

  • 研究对SSc相关PH患者、无PH的SSc患者及健康对照的内皮祖细胞来源内皮细胞进行微阵列实验以筛选候选基因。
  • 通过定量夹心酶联免疫吸附试验检测血清候选基因表达,并通过免疫组化检测病变肺组织。
  • 在自发出现SSc样特征及强烈肺血管重塑的fos相关抗原2转基因(Fra-2-Tg)小鼠中评估候选基因的功能重要性。

主要发现

  • 微阵列实验显示基质金属蛋白酶10(MMP10)基因是SSc相关PH内皮祖细胞来源内皮细胞中上调最显著的基因。
  • 与无PH的SSc患者和健康对照相比,SSc相关PH患者循环血清proMMP10浓度显著升高。
  • 在SSc相关PH患者和Fra-2-Tg小鼠的肺组织中,均发现远端肺动脉增厚管壁有强烈的MMP10染色。
  • 每日给予Fra-2-Tg小鼠中和性抗MMP10抗体未显著影响肺纤维化的发生和严重程度,但逆转了已建立的PH,并通过减少细胞增殖、细胞存活和血小板衍生生长因子信号轴显著减轻肺血管重塑。

临床怎么用

  • MMP10可能作为SSc相关PH的潜在治疗靶点,其阻断在动物模型中可逆转已建立的PH并减轻肺血管重塑。

局限性

  • 原文未报告研究局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To elucidate the role of gene candidates involved in pulmonary hypertension (PH) associated with systemic sclerosis (SSc). METHODS: Gene candidates were identified through microarray experiments performed on Affymetrix GeneChip Human Exon 1.0 ST arrays in endothelial progenitor cell (EPC)-derived endothelial cells (ECs) obtained from patients with SSc-associated PH, patients with SSc without PH, and healthy control subjects. Expression of identified gene candidates was assessed by quantitative sandwich enzyme-linked immunosorbent assay in the serum, and by immunohistochemistry in lesional lung tissue. The functional importance of the identified gene candidates was then evaluated in fos-related antigen 2-transgenic (Fra-2-Tg) mice that spontaneously develop SSc-like features associated with an intense pulmonary vascular remodeling. RESULTS: Microarray experiments revealed that the matrix metalloproteinase 10 (MMP-10) gene was the top up-regulated gene in SSc-associated PH EPC-derived ECs. Circulating serum proMMP10 concentrations were markedly increased in patients with SSc-associated PH compared to SSc patients without PH and healthy controls. Consistent with these observations, a strong MMP10 staining of the thickened wall of distal pulmonary arteries was found both in the lungs of patients with SSc-associated PH and in the lungs of Fra-2-Tg mice. Daily treatment of Fra-2-Tg mice with neutralizing anti-MMP10 antibodies did not significantly affect the development and severity of pulmonary fibrosis, but did reverse established PH and markedly reduced pulmonary vascular remodeling by reducing cell proliferation, cell survival, and the platelet-derived growth factor signaling axis. CONCLUSION: Gene expression profiling of EPC-derived ECs identified MMP10 as a novel candidate gene in SSc-associated PH. MMP10 is overexpressed in the serum and pulmonary arteries of patients with SSc-associated PH, and its blockade alleviates PH in the Fra-2-Tg mouse model. MMP10 appears to be a prospective treatment target for this devastating disorder.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Avouac J, Guignabert C, Hoffmann-Vold AM, et al. Role of Stromelysin 2 (Matrix Metalloproteinase 10) as a Novel Mediator of Vascular Remodeling Underlying Pulmonary Hypertension Associated With Systemic Sclerosis. Arthritis Rheumatol. 2017. PMID: 28805015. doi:10.1002/art.40229

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。